United States · Bill · HR
H.R. 8641 (117th)
Orphan Drug COVID–19 Mitigation Act of 2022
Introduced
2 August 2022
Last action
—
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
—
Subjects
Discovery layer
Source updated
3 January 2025
Summary
Orphan Drug COVID-19 Mitigation Act of 2022 This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 2 August 2022
Introduced in House (PDF)
Introduced in House · EN · 2 August 2022
Introduced in House
summary · EN · 2 August 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/8641
- Open data entity: https://api.congress.gov/v3/bill/117/hr/8641